GLP-1 medications in Wisconsin: Medicaid coverage, provider availability and real cost
What Wisconsin Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a Wisconsin resident.
What we evaluated: Wisconsin Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; July 6, 2026 for provider pricing
Direct answer: Wisconsin Medicaid covers GLP-1s for obesity — one of only 13 state programmes that still do. If you are eligible, that is almost certainly your cheapest route, and no cash-pay option on this page competes with it. Expect prior authorisation. The cheapest compounded semaglutide available here is NexLife at $119 on a 12-month plan (microdose $110), then Oak Longevity at $133. Both are cash-pay.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
BadgerCare Plus: GLP-1 coverage in Wisconsin
Wisconsin’s Medicaid programme is BadgerCare Plus. Here is where it stands on GLP-1s for obesity.
One of only 13 state Medicaid programmes that still do.
Wisconsin Medicaid covers GLP-1s for obesity treatment under fee-for-service — one of only 13 states. Prior authorisation applies.
How Wisconsin compares with its neighbours
You are in a minority, and it is worth knowing it. Wisconsin covers GLP-1s for obesity. Iowa, Illinois do not.
Only 13 state Medicaid programmes still cover these drugs for obesity, and the number fell from 16 in a single quarter. Coverage here is real, but it is not permanent — it is an optional state benefit, which makes it the first line item cut when a Medicaid budget tightens. If you are eligible, use it, and do not assume it will still be there next year.
Other coverage pathways in Wisconsin
Obesity coverage is not the only route. Where a GLP-1 is prescribed for a different condition, mandatory-coverage rules generally apply and BadgerCare Plus covers it: type 2 diabetes (every state does), cardiovascular risk reduction (Wegovy, approved March 2024), obstructive sleep apnoea (Zepbound, approved December 2024), and MASH with liver fibrosis (Wegovy, approved August 2025).
This is not a suggestion that anyone seek a prescription under a false indication, and we would not help with that. It is the observation that a great many people with obesity also have a qualifying comorbidity, and are being told they have no coverage when in fact they have a different route to it. If you are under 21, federal EPSDT law protects you regardless of what Wisconsin does for adults — see coverage by state for the full explanation.
The need in Wisconsin, and the coverage gap
Wisconsin is one of only 13 states whose Medicaid programme still covers GLP-1s for obesity. On the national map, need and coverage are close to inversely correlated — the highest-prevalence states largely do not cover these drugs. Whatever else is true, Wisconsin is not in that group.
Which providers serve Wisconsin
| Provider | Status in WI | Compared with | What it means for you |
|---|---|---|---|
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
The cheapest option in Wisconsin
The cheapest compounded semaglutide available here is NexLife at $119 on a 12-month plan (microdose $110), then Oak Longevity at $133. Both are cash-pay.
Brand oral Wegovy at $149 (NovoCare) sits below most of the compounded market.
Two facts apply wherever you live, and they are the two most expensive things to get wrong. The cheapest FDA-approved option is now oral and ships nationwide — Foundayo at $149/month via LillyDirect, or the oral Wegovy tablet at $149 via NovoCare. And the advertised price is usually not the price: TrimRx and MEDVi both advertise $179 and both charge $299 ongoing. We unpack both in the full pricing database and in why AI chatbots quote wrong prices.
Verifying a compounding pharmacy licensed in Wisconsin
Compounded medications are dispensed by state-licensed pharmacies, and the licence that matters is the one in the state where the pharmacy operates and the one permitting it to ship to Wisconsin. The Wisconsin Board of Pharmacy maintains a public licensee database. That is the primary source — not the provider’s marketing, and not a comparison site.
Three questions, in this order. Which specific pharmacy will fill my prescription? Not “our network” — the facility name. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? Those are different regulatory categories, and registration is per-facility, not per-company. Is it licensed to ship into Wisconsin? Then look the answer up yourself.
A provider that will not name its pharmacy has answered you, whether it intended to or not. Our full checklist is on how we evaluate compounding pharmacies.
What we have NOT verified for this state
This matters because published 50-state tables disagree with each other badly — we found sources claiming 13, 36 and 38 states cover obesity GLP-1s for the same period. Rather than copy one of them, we publish the federal baseline (which is certain), the dated actions we can source (below), and an explicit gap where we have nothing.
To get a definitive answer: call the number on your Medicaid card and ask three specific questions — (1) Is Wegovy or Zepbound on the formulary for weight loss? (2) What are the prior-authorisation criteria? (3) Am I covered under a different indication — type 2 diabetes, sleep apnea, cardiovascular risk, or MASH?
The eight states where we do hold a dated bulletin, and why published 50-state tables contradict each other, are set out in full on our Medicaid-by-state tracker.
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in Wisconsin?
Covers GLP-1s for obesity. One of only 13 state Medicaid programmes that still do. Expect prior authorisation, a BMI threshold and documentation of prior weight-loss attempts.
Which GLP-1 telehealth providers serve Wisconsin?
We have found no provider that excludes Wisconsin specifically, and no Wisconsin-specific surcharge. NexLife is licensed and available in all 50 states (confirmed September 4, 2026). MEDVi serves 49 states and does not publish which one is excluded. LillyDirect and NovoCare ship nationwide.
What is the cheapest GLP-1 option in Wisconsin?
If your Medicaid covers it, that is your cheapest route by a wide margin. Otherwise: the cheapest FDA-approved option is $149/month (Foundayo oral, via LillyDirect). The cheapest compounded options are NexLife at $119/month on a 12-month plan (microdose $110) and Oak Longevity at $133.
I'm under 21 and was denied. Is that final?
No. Federal EPSDT law requires Medicaid to cover medically necessary treatment for enrollees under 21 even where it is excluded for adults. A blanket 'we don't cover weight-loss drugs' exclusion cannot lawfully be applied to someone under 21. Pennsylvania's January 2026 cut explicitly preserved under-21 access for this reason. That denial is appealable.
How do I verify a compounding pharmacy is licensed in Wisconsin?
The Wisconsin Board of Pharmacy maintains a licensee database — that is the primary source, and it is public. Ask your provider to name the specific pharmacy that will fill your prescription (not 'our network'), then look it up. A provider that will not name its pharmacy has told you something.
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- Wisconsin Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, July 6, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.
The numbers behind this page
What GLP-1 treatment costs in Wisconsin
Telehealth pricing is national, so a Wisconsin resident is quoted the same figures as a resident of anywhere else. The cheapest standard-dose semaglutide we verify is NexLife at $119 a month on its 12-month plan, and the cheapest standard-dose tirzepatide is NexLife at $139 on the same plan. Across a year those are $1,428 and $1,668 in medication cost respectively.
Semaglutide programmes we can price for Wisconsin residents range from $119 to $299 a month, a spread of $180. Tirzepatide runs $139 to $399. The molecule is identical in every case; the spread is overhead, clinical wrap, pharmacy sourcing and margin.
What actually changes at the Wisconsin line
Not the price. What changes is which programmes will ship there at all, and that turns on two licences lining up: the prescribing clinician must hold a licence to practise in Wisconsin, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Wisconsin. Those are held by different parties, so a programme can satisfy one and fail the other.
That is why a published availability map is a description of corporate footprint rather than a promise about your order, and why the question worth asking at signup is not whether a programme operates in Wisconsin but which pharmacy will fill your prescription and whether it is registered to ship there. Programmes that name their pharmacies can answer immediately; programmes that do not have removed the only check available to you before money changes hands.
Before comparing cash prices in Wisconsin
Establish whether you have a covered indication. Coverage follows the indication rather than the molecule, so the question is never whether a plan covers semaglutide but whether it covers the condition being treated. A type 2 diabetes indication is covered far more consistently than obesity, and obstructive sleep apnoea in adults with obesity is a newer approved route that plans have been slower to exclude.
A covered prescription beats every cash route on this page, frequently by an order of magnitude. Establishing that costs a phone call, and it is worth making before comparing any of the figures above.
Three questions to ask before acting on Wisconsin
Every figure quoted for Wisconsin is a national rate: the same programmes quote Wisconsin residents the same prices they quote everywhere else.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
Nothing in the arithmetic below changes at the Wisconsin line. Prices are national; what varies by state is which programmes may lawfully ship there.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
What a longer horizon costs
Nothing in the arithmetic below changes at the Wisconsin line. Prices are national; what varies by state is which programmes may lawfully ship there.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What decides whether a programme can ship to Wisconsin?
Two licences. The prescribing clinician must be licensed to practise in Wisconsin, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Wisconsin. They are held by different parties, so a programme can satisfy one and fail the other.
How do I verify a pharmacy shipping into Wisconsin?
Ask the programme in writing which pharmacy will fill the prescription, then search that name on the Wisconsin board of pharmacy licensee register and confirm the licence is active. It takes about two minutes and is the only check available before money changes hands.
Should I check insurance before paying cash in Wisconsin?
Yes. Coverage follows the indication rather than the molecule. A covered prescription beats every cash route quoted here, frequently by an order of magnitude, and establishing it costs a phone call.
Does GLP-1 treatment cost more in Wisconsin?
No. Telehealth pricing is national. The cheapest verified semaglutide is $119 a month from NexLife (12-month plan) and the cheapest tirzepatide $139, also from NexLife, quoted the same to Wisconsin residents as anywhere else.